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Abstract 
Introduction. Since 2002, the European Strategy Forum on Research Infrastructures 
identified the needs for Research Infrastructures (RIs) in Europe in priority fields of 
scientific research and drafted a strategic document, the ESFRI Roadmap, defining the 
specific RIs essential to foster European research and economy. The Biological and Med-
ical Sciences RIs (BMS RIs) were developed thanks to the active participation of many 
institutions in different European member states associated to address the emerging 
needs in biomedicine and, among these, the Italian National Institute of Health (ISS), 
in virtue of its role in public health and research, has been specifically involved in the 
national development and implementation of three RIs: the Biobanking and Biomolecu-
lar Resources Research Infrastructure (BBMRI), the European Advanced Translational 
Research Infrastructure in Medicine (EATRIS) and the European Clinical Research In-
frastructures Network (ECRIN). 
Aim. This article outlines the design and development of these RIs up to the recent 
achievement of the ERIC status, their importance in the Horizon 2020 programme and 
their societal and economic potential impact, with special attention to their development 
and significance in Italy.
Conclusions. The ISS plays a unique role in fostering a coordinated participation of 
excellence Italian institutes/facilities to different European biomedical RIs, thus contrib-
uting to health innovation, healthcare optimization, and healthcare cost containment.
INTRODUCTION
Research Infrastructures (RIs) are facilities, resources 
or services that constitute large sets of research equip-
ment or instruments and represent or complement 
knowledge resources such as collections, archives and 
databases. RIs can be concentrated on a single spot, 
distributed or virtual (enabling services electronically). 
They often require a structured information system for 
data management and for enabling information and 
communication [1].
To avoid duplication of similar RIs in the European 
area and to foster a coordinated approach regarding 
public policies and funding, at the beginning of 2002, 
the European Strategy Forum on Research Infrastruc-
tures (ESFRI) was established on proposal by the 
Council of the European Union. Constituted by dele-
gates of Research Ministries of the Member States and 
Associated Countries and including a representative of 
European Commission (EC), the ESFRI has the objec-
tive of identifying and addressing the scientific needs 
of RIs in Europe for the next 10-20 years. Its mission 
is to support a coherent and strategy-led approach to 
policy-making on new and existing pan-European and 
global RIs. The ESFRI Roadmap was first published in 
2006, where 35 projects were identified in all the fields 
of science [2]. The Roadmap was updated by ESFRI 
in 2008 and 2010, bringing the total number of RIs of 
pan-European relevance to 48 [1, 3]. The ESFRI Road-
map addresses all scientific disciplines that require a 
large scale RI with a joint effort on European or interna-
tional scale. The proposed infrastructures are grouped 
by research field: Social Sciences & Humanities, En-
vironmental Sciences, Energy, Biological and Medical 
Sciences, Material Sciences and Analytical Facilities, 
Physical Sciences & Engineering. These projects are 
very diverse in size and character and are at very differ-
ent stage of development.
The implementation of the projects on the ESFRI 
Roadmap is a priority for both ESFRI and the EC; for 
this reason, the ESFRI Implementation Group was set 
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up in 2011 to address issues related to the acceleration 
and improvement of the implementation and proce-
dures of RIs. According to Implementation Group (IG) 
definitions [4], an ESFRI project can be considered to 
be under implementation when the following condi-
tions are met: i) agreed statutes or other legal provisions 
for the construction and operation of the RI are pre-
sent; ii) a stable legal governance structure is in place; 
and iii) there is budget commitment for the different 
stages of the RI. Moreover, the IG considers an ESFRI 
project to be in the preparatory phase, when it has an 
officially allocated budget from the European Com-
mission for a specific time period in order to arrange 
the legal, governance and financial conditions to start 
the implementation of the project. The IG also defines 
the interim phase for projects that ended the official 
preparatory phase, but that do not yet meet the legal, 
governance and financial conditions that are necessary 
to be considered as under implementation.
According to the EC Memo [5] on ESFRI RIs pub-
lished in 2012, about half of the ESFRI projects are 
now in their implementation phase. These RIs are listed 
in Table 1.
FROM RI PROJECTS TO EUROPEAN 
RESEARCH INFRASTRUCTURE 
CONSORTIUM (ERIC)
A major difficulty in setting up pan European RIs 
was the lack of an adequate legal framework allowing 
the creation of appropriate partnerships. In an attempt 
to enhance flexibility and opportunities for RIs, the 
European Council, responding to requests from EU 
countries and the scientific community, introduced 
a scheme for better governance through a new legal 
framework, the European Research Infrastructure Con-
sortium (ERIC) [6]. ERIC aims to facilitate the joint 
establishment and operation of RIs involving at least 
three Member States on the basis of Article 171 of the 
European Treaty [7]. RIs in the ERIC framework will 
be able to operate as legal entities, adapting their indi-
vidual specific requirements and enhancing their flex-
ibility and capability in attracting funding from various 
sources (non-EU countries, private sector).
On 3 December 2012, the Commission adopted a 
proposal for a Council Regulation amending the Regu-
lation EC 723-2009 concerning the ERIC [8]. The aim 
was to facilitate the participation of associated countries 
in ERICs and ensure that their contributions to ERICs 
are reflected in terms of voting rights on the same foot-
ing as Member States for ERICs that are hosted by the 
associated countries.
To set up an ERIC, the following steps are necessary:
- at least three Member States must agree to establish 
and operate together a research infrastructure. Associ-
ated countries, third countries and intergovernmental 
organizations may also be members; 
- the members agree on statutes ruling governance, 
intellectual property rights policy, financing, etc.;
- the seat has to be in an EU-Member State or in a 
country associated to the EU Framework programs;
- the members submit the file to the Commission, 
which, with the aid of independent experts, examines 
whether the conditions of the ERIC Regulation are ful-
filled. After that, a committee composed of representa-
tives of the EU Member States gives an opinion on the 
file by qualified majority, following which the Commis-
sion decides on the application.
The application is valid if it is supported by at least 
three Member States and shall contain: i) the proposed 
statutes of the ERIC; ii) the technical and scientific de-
scription of the infrastructure (business plan): iii) the 
declaration of the host Member State recognizing the 
ERIC as an international organization exempted from 
VAT and excise duty according to the pertinent direc-
tives; iv) the agreement between the Members of the 
ERIC on the limits and conditions of the tax exemption.
To date, six RIs (CLARIN, SHARE, EATRIS, ESS, 
ECRIN and BBMRI) (Table 1) have been established as 
ERIC (http://ec.europa.eu/research/infrastructures/in-
dex_en.cfm?pg=eric). Five other applications have been 
received at the Commission at the present time (Table 1).
BIOLOGICAL AND MEDICAL SCIENCES RIs 
(BMS RIs) AND THE ITALIAN ROADMAP
The pan-European BMS RI projects on the ESFRI 
roadmap provide an interdisciplinary, innovative envi-
ronment in the field of life sciences and health research 
where world-leading investigators conduct forefront 
research using open access to cutting-edge technolo-
gies and scientific data. BMS RIs will play a key role 
in closely linking basic research to medical application, 
providing services, training and access to technology for 
scientists in academia as well as industry.
Among the BMS RIs, on November 2013 the Biobank-
ing and Biomolecular Resources Research Infrastruc-
ture (BBMRI), the European Advanced Translational 
Research Infrastructure in Medicine (EATRIS) and the 
European Clinical Research Infrastructures Network 
(ECRIN) were awarded the ERIC status by the EC. 
BBMRI
Early in 2009 TIME Magazine identified biobanks as 
one of the 10 ideas changing the world [9] and ESFRI 
recognized in the first roadmap the research biobanking 
as an area of strategic European interest [10]. Consist-
ent with this vision, a pan-European BBMRI for bio-
medical and biological research in Europe was funded 
(www.bbmri.eu). The project intended to meet the 
growing need for harmonized approaches to establish 
and manage biorepositories, and for the implementa-
tion of a European infrastructure built on existing sam-
ple collections, resources, technologies and expertise, 
connecting them in a European network. 
The mission of BBMRI is to sustainably secure ac-
cess to biological resources required for health-related 
research intended to improve the prevention, diagno-
sis and treatment of disease as well as to promote the 
health of the European citizens. Biomedical quality-as-
sessed samples and data are essential for academic and 
industry-driven research to treat and prevent human 
diseases [11, 12].
BBMRI has the following objectives:
- harmonizing standards for sample collection, stor-
age and analysis;
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Category RI short name Name Mission
Social Sciences 
and Humanities
CESSDA Council of Eu-
ropean Social 
Science Data 
Archives
To provide and facilitate access for researchers to high quality data 
for social sciences
CLARIN-ERIC* Common 
Language Re-
sources and 
Technology 
Infrastructure
To advance research in humanities and social sciences by giving 
researchers unified single sign-on access to a platform which inte-
grates language-based resources and advanced tools at a European 
level
DARIAH** Digital Re-
search Infra-
structure for 
the Arts and 
Humanities 
To enhance and support digitally-enabled research across the hu-
manities and arts
ESS-ERIC* European So-
cial Survey 
To chart and explain the interaction between Europe’s changing insti-
tutions and the attitudes, beliefs and behavior patterns of its diverse 
populations
SHARE-ERIC* Survey of 
Health, Ageing 
and Retirement 
in Europe
To build an infrastructure of micro data of households and individuals 
necessary to understand individual and societal ageing
Environmental 
Sciences
ICOS** Integrated Car-
bon Observa-
tion System 
To provide the long-term observations required to understand the 
present state and predict future behavior of the global carbon cycle 
and greenhouse gas emissions
EURO-ARGO** Global Ocean 
Observing In-
frastructure 
To allow active coordination and strengthening of the European con-
tribution to the international Argo programme, source of information 
and data over the ocean’s interior
Lifewatch** Science and 
Technology 
Infrastructure 
for Research on 
Biodiversity and 
Ecosystems
To provide an analytical platform for the modelling and simulation of 
both existing and new data on biodiversity to enhance the knowledge 
of biodiversity functioning and management
Energy JHR Jules Horowitz Reactor
To study the materials and fuel behavior for nuclear
power plants
Biological 
and Medical 
Sciences
BBMRI-ERIC* Biobanking and 
Biomolecular 
Resources 
Research Infra-
structure 
To form an interface between biological specimens and data (from 
patients and European populations) and top-level biological and 
medical research
EATRIS-ERIC* European Ad-
vanced Transla-
tional Research 
Infrastructure in 
Medicine 
To provide a new development pathway, open to researchers and 
companies in need of support for advancing biomedical innovations
ECRIN-ERIC* European Clini-
cal Research 
Infrastructures 
Network 
To support multinational clinical research projects in Europe
ELIXIR European 
Life-science 
Infrastructure 
for Biological 
Information
To act as a platform for collection, storage, validation, dissemination 
and utilisation of biological data
INFRAFRON-
TIER
European In-
frastructure for 
Phenotyping 
and Archiving of 
Model Mamma-
lian Genomes
To provide access to scientific platforms, data and services for the
systemic phenotyping, archiving and distribution of mouse models
INSTRUCT Integrated Struc-
tural Biology 
Infrastructure
To provide open access to state-of-the art structural biology technolo-
gies for researchers
Table 1
Research infrastructures in the implementation phase [5]
(continues)
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Category RI short name Name Mission
Social Sciences 
and Humanities
CESSDA Council of Eu-
ropean Social 
Science Data 
Archives
To provide and facilitate access for researchers to high quality data 
for social sciences
CLARIN-ERIC* Common 
Language Re-
sources and 
Technology 
Infrastructure
To advance research in humanities and social sciences by giving 
researchers unified single sign-on access to a platform which inte-
grates language-based resources and advanced tools at a European 
level
DARIAH** Digital Re-
search Infra-
structure for 
the Arts and 
Humanities 
To enhance and support digitally-enabled research across the hu-
manities and arts
ESS-ERIC* European So-
cial Survey 
To chart and explain the interaction between Europe’s changing insti-
tutions and the attitudes, beliefs and behavior patterns of its diverse 
populations
SHARE-ERIC* Survey of 
Health, Ageing 
and Retirement 
in Europe
To build an infrastructure of micro data of households and individuals 
necessary to understand individual and societal ageing
Environmental 
Sciences
ICOS** Integrated Car-
bon Observa-
tion System 
To provide the long-term observations required to understand the 
present state and predict future behavior of the global carbon cycle 
and greenhouse gas emissions
EURO-ARGO** Global Ocean 
Observing In-
frastructure 
To allow active coordination and strengthening of the European con-
tribution to the international Argo programme, source of information 
and data over the ocean’s interior
Lifewatch** Science and 
Technology 
Infrastructure 
for Research on 
Biodiversity and 
Ecosystems
To provide an analytical platform for the modelling and simulation of 
both existing and new data on biodiversity to enhance the knowledge 
of biodiversity functioning and management
Energy JHR Jules Horowitz Reactor
To study the materials and fuel behavior for nuclear
power plants
Biological 
and Medical 
Sciences
BBMRI-ERIC* Biobanking and 
Biomolecular 
Resources 
Research Infra-
structure 
To form an interface between biological specimens and data (from 
patients and European populations) and top-level biological and 
medical research
EATRIS-ERIC* European Ad-
vanced Transla-
tional Research 
Infrastructure in 
Medicine 
To provide a new development pathway, open to researchers and 
companies in need of support for advancing biomedical innovations
ECRIN-ERIC* European Clini-
cal Research 
Infrastructures 
Network 
To support multinational clinical research projects in Europe
ELIXIR European 
Life-science 
Infrastructure 
for Biological 
Information
To act as a platform for collection, storage, validation, dissemination 
and utilisation of biological data
INFRAFRON-
TIER
European In-
frastructure for 
Phenotyping 
and Archiving of 
Model Mamma-
lian Genomes
To provide access to scientific platforms, data and services for the
systemic phenotyping, archiving and distribution of mouse models
INSTRUCT Integrated Struc-
tural Biology 
Infrastructure
To provide open access to state-of-the art structural biology technolo-
gies for researchers
- harmonizing data collection and the associated da-
tabase infrastructure;
- providing ethical and legal guidance;
- developing a sustainable funding model for biobanks.
During the preparatory phase, ended in January 
2011, BBMRI has grown into a 54-member consortium 
with more than 225 associated organisations, largely 
biobanks from over 30 countries, establishing an inter-
active catalogue of associated biobanks (www.bbmri.
eu). At the end of the preparatory phase, 14 Member 
States signed the declaration of intention (Memoran-
dum of Understanding) to participate in BBMRI-ER-
IC. During this phase, BBMRI Charter, Statute and 
business plan, necessary to activate the formal request 
of the consortium to the EC, have been refined and 
adopted.
On August 9th, 2012 BBMRI-ERIC application has 
been submitted to EC. Hence BBMRI is now ap-
proaching the operative phase with a headquarter in 
Graz (Austria) and common services in other Mem-
ber countries. In each participating State, according 
to BBMRI Statutes, a National hub to coordinate the 
activities of the national biobanks and to interface the 
European central coordination headquarter has been 
established. The BBMRI-ERIC Inauguration Confer-
ence took place on September 16th, 2013 and during 
the event National Nodes have been formally pre-
sented and on November 22nd 2013, BBMRI was of-
ficially awarded the Community legal framework for 
a ERIC (http://ec.europa.eu/research/infrastructures/
index_en.cfm?pg=eric). In continuity with the work 
performed during the preparatory phase, the Istituto 
Superiore di Sanità (ISS), by a joint mandate of the Ital-
ian Ministries of Health and Education, University and 
Research, signed the national participation to BBMRI-
ERIC and established the National Node of BBMRI 
(www.bbmri.it). The Italian node of BBMRI has held 
its launch or “kick-off” meeting on October 8th, 2013 
during the ESBB’s Annual Conference (www.esbb.org/
verona/).
So far the founding BBMRI-ERIC members are: 
Austria, Belgium, Czech Republic, Estonia, Finland, 
Greece, Italy, the Netherlands, Malta, Sweden, France, 
Germany. Norway, Poland, Switzerland and Turkey 
joined as Observer member.
EATRIS
In recent years, a large number of editorial articles 
published in top journals have emphasized the impor-
tance of strategic national and international initiatives 
for the promotion of biomedical translational research 
[13]. In fact, there is a general concern (shared by the 
scientific community, patients’ organizations, policy-
makers and national governments) about major bot-
tlenecks which hamper the translation of the results 
stemming from basic research into clinical experimen-
Materials 
Sciences
ESFR European Syn-
chrotron Radia-
tion Facility
To operate the most powerful high energy synchrotron light source in 
Europe and bring together a wide range of disciplines including phys-
ics, chemistry and materials sciences as well as biology, medicine, 
geophysics and archaeology
ESS** European Spall-
ation Source 
To complete and operate the best and most powerful neutron source 
in the world by the end of the decade
ILL 20/20 To act as a productive and reliable source of slow neutrons for the 
study of condensed matter
European 
XFEL
European Hard 
X-ray Free 
Electron Laser
To be a world leading facility for the production of intense, short puls-
es of X-rays for scientific research in a wide range of disciplines
E-ELT European Ex-
tremely Large 
Telescope
To be the largest optical/near-infrared telescope in the world
SKA Square Kilome-
tre Array
To be the world’s largest and most sensitive radio telescope
ELI Extreme-Light-
Infrastructure
To provide high-quality access to the international research commu-
nity for prospective applications of ultra-intense and ultra-short laser 
pulses
FAIR Facility for Anti-
proton and Ion 
Research
To provide high energy primary and secondary beams of ions of high-
est
intensity and quality, including an ‘antimatter beam’ of antiprotons al-
lowing forefront research in different disciplines of physics
SPIRAL 2 Facility for the 
production and 
study of rare 
isotope radioac-
tive beams
To deliver stable and rare isotope beams with intensities not yet 
available with present machines
E-infrastructure PRACE
Partnership 
for Advanced 
Computing in 
Europe
To provide access to distributed pan-European world class high 
performance computing and data management resources 
and services
*RIs which have been established as ERIC
**Facilities which have submitted ERIC application to EC
Table 1 (Continued)
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tation and medical practice. In 2006 a European call 
for proposals for preparatory phase for the construc-
tion of some European RIs particularly relevant for the 
promotion of biomedical translational research of ad-
vanced therapies was launched. Among the proposals, 
the EATRIS turned out to be one of special potential 
importance for the development of biomedical trans-
lational research and advanced therapies. In fact, an 
evaluation process assessing scientific excellence, im-
pact, and possible implementation identified EATRIS 
proposal as one of the six projects to receive 7th Frame-
work Program (FP7) funding for a preparatory phase 
(2008-2010). 
After this preparatory phase and a one-year transition 
phase supported by the participating Member States, in 
2012 EATRIS entered its construction phase (Partners 
carry out construction on major upgrade as agreed in 
consortium agreement). In 2011 the EATRIS headquar-
ters (namely EATRIS Coordination and Support) were 
opened in Amsterdam. These headquarters function as 
a broker office matching clients and translational ser-
vice providers. On the 1st of June 2012, EATRIS applied 
for the legal status of ERIC with the support of 9 Mem-
ber States (Czech Republic, Denmark, Spain, Finland, 
France, Italy, Norway, Estonia, The Netherlands). 
From the 7th of November 2013 EATRIS is a new 
official European organisation under the ERIC frame-
work (http://ec.europa.eu/research/infrastructures/in-
dex_en.cfm?pg=eric).
EATRIS aims to support academia, SME’s and large 
industry in translating results from bench to bedside by 
providing high quality services necessary for European 
researchers interested in the transfer of their discover-
ies into clinical studies (up to the early Phase II trials). 
The translational research areas of focus for EATRIS 
Centres are based on product types as well as disease 
areas. The 5 product types covered in EATRIS (mo-
lecular imaging and tracing, vaccines, biomarkers, small 
molecules and advanced therapeutic medicinal prod-
ucts) cover the range of applications from preventive 
agents via diagnostics to therapeutics and they also re-
flect the areas of greatest potential in translational re-
search and collectively offer a vastly superior research 
structure with respect to that possible with individual 
institutions. 
Each country is represented by one or more research 
institutions or national networks, which constitute a na-
tional node (www.eatris.eu). The ISS was delegated by 
the Italian Ministry of Health, in agreement with the 
Italian Ministry of Education, University and Research, 
to participate in the EATRIS preparation and transition 
phases and, more recently, to represent Italy in signing 
the formal participation to the EATRIS-ERIC. The ISS 
also promoted the participation of several other Ital-
ian institutions and networks in EATRIS creating the 
initial national node of EATRIS, named IATRIS (Ital-
ian Advanced Translational Research Infrastructures in 
Medicine) (www.iatris.it). IATRIS’ main objective is to 
overcome the bottlenecks which delay both the trans-
fer of basic research results into clinical applications 
and the feedback of clinical observations to the basic 
investigation. IATRIS represents a unique network of 
academic institutions and research entities finalized to 
provide open multidisciplinary services and centralized 
facilities instrumental for projects of translational medi-
cine under a national coordination. Most detailed in-
formation concerning the participating institutions and 
ongoing initiatives can be found on the IATRIS website 
(www.iatris.it). All this is expected to ensure a more ef-
fective and rapid transfer of the scientific knowledge 
into prevention, diagnosis and treatment of diseases. 
IATRIS will represent the Italian infrastructure system 
in EATRIS-ERIC.
ECRIN
ECRIN is a distributed ESFRI roadmap RI designed 
to promote cooperation in clinical research in Europe. 
ECRIN was listed on the first edition of the ESFRI 
Roadmap and it began as a European research project 
funded under the Framework Programme 6 (FP6). 
The current RI is the result of several EU projects car-
ried out in recent years: i) the FP6 ECRIN-RKP project 
(Reciprocal Knowledge Programme, 2004-2005) help-
ing to identify the bottlenecks and define a strategy; ii) 
the FP6 ECRIN-TWG (Transnational Working Groups, 
2006-2008) leading to the development of generic tools 
and procedures for multinational clinical research; and 
iii) the FP7-funded preparatory phase (ECRIN-PPI, 
Preparatory Phase for the Infrastructure, 2008-2011), 
designed to further structure the RI and to start provi-
sion of support to ‘pilot’ multinational clinical studies, 
in order to test the organization and the procedures. 
The new FP7-funded project ECRIN-IA (ECRIN 
Integrating Activity, 2011-2015) aims to help ECRIN 
expand the infrastructure created through the previous 
phases and plans, among other objectives, to support 
the structuring of networks in three strategic areas (rare 
disease, medical devices and nutrition) [14]. 
The mission of ECRIN is to: 
- facilitate the conduct of multinational clinical stud-
ies in Europe by harmonizing national procedures and 
providing a “one-stop-shop” network of services to in-
vestigators and sponsors in multinational clinical re-
search studies, mainly in the academic and SME sector;
- improve the quality and efficiency of European clin-
ical research, ensuring scientific excellence to clinical 
research projects [15];
- lay the foundations for a more effective interna-
tional cooperation, able to boost European research, in 
order to make Europe a single area for clinical research.
ECRIN is based on the connection of national net-
works of academic infrastructures for clinical research, 
Clinical Research Centres and Clinical Trial Units, able 
to provide information, consultancy and services for 
multinational clinical trials (www.ecrin.org). 
Currently it covers 14 European countries (Austria, 
Belgium, Denmark, Finland, France, Germany, Hun-
gary, Ireland, Italy, Poland, Spain, Sweden, Switzerland 
and the UK) mainly participating with national nodes/
hubs or with institutions directly or indirectly involved 
in clinical research. All institutions or national nodes/
hubs are connected to the central coordination body, 
established in Paris at INSERM, through the network 
of European Correspondents (EuCos).
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ECRIN has recently acquired the ERIC status 
(http://ec.europa.eu/research/infrastructures/index_
en.cfm?pg=eric): Italy signed the statutes as a Member 
together with Germany, Spain, Portugal and France 
(host country and coordinator of the consortium). The 
ERIC status will allow ECRIN to act as a single inter-
national legal entity and will provide with the capacity 
to propose a single task delegation contract with the 
sponsor of the clinical trial [14]. 
RIS IN THE COMING 8TH FRAMEWORK 
PROGRAMME FOR RESEARCH AND 
INNOVATION “HORIZON 2020”
“Horizon 2020” is the new, integrated funding system 
that will cover all research and innovation funding cur-
rently provided through the Framework Programme for 
Research and Technical Development, the Competi-
tiveness and Innovation Framework Programme (CIP) 
and the European Institute of Innovation and Technol-
ogy (EIT), bringing together these different types of 
funding in a coherent and flexible manner. This € 80 
billion package for research and innovation funding will 
enter into force on 1st of January 2014, after the end of 
FP7 on 31st of December 2013, and will run from 2014 
to 2020, with the aim to secure global competitiveness 
and create new growth and jobs in Europe. Horizon 
2020 will be based on three main themes: excellence in 
science, tackling societal challenges and creating indus-
trial leadership and competitive frameworks. 
In the European scenario, RIs are seen as pivotal 
instruments to foster innovation through internation-
al cooperation, provided these instruments are used 
wisely and efficiently. Indeed, in order to help Europe 
to respond to grand challenges in science, industry and 
society, there is a need to ensure the implementation, 
long-term sustainability and efficient operation of new 
and existing RIs. For this reason, RIs have been rec-
ognized as one of four key objectives of the “Excellent 
Science” pillar within the EC’s proposal for Horizon 
2020 [16]. In particular, funding of European RIs will 
contribute to:
- facilitate and support the implementation and op-
eration of ESFRI and other world-class research infra-
structures;
- integrate and facilitate access to national research 
infrastructures;
- continue supporting the development, deployment 
and operation of e-infrastructures;
- foster the innovation potential of research infra-
structures and their human capital;
- reinforce the European policy and international co-
operation.
RIs IN THE INNOVATIVE MEDICINES 
INITIATIVE 2 (IMI 2) RESEARCH FUNDING 
INITIATIVE
IMI 2 (www.imi.europa.eu/content/imi-2) is a Joint 
Technology Initiative (JTI) bringing together compa-
nies, universities, public laboratories, innovative SMEs, 
patient groups and regulators. It will pave the way for 
breakthrough vaccines, medicines and treatments to 
tackle Europe’s growing health challenges through a 
concentrated and combined science and innovation ef-
fort. It will help secure the future international competi-
tiveness of Europe’s pharmaceutical industry. 
The aim of IMI 2 is to enable an appropriate Euro-
pean-level research and innovation response that will 
make a crucial contribution to delivering better health 
and wellbeing for all, and positioning Europe as a leader 
in the rapidly expanding global markets for health and 
wellbeing innovations. 
Delivering innovative solutions can only be achieved 
through combining the expertise of large and mid-size 
pharmaceutical and biotech companies (and associated 
contract research organizations), academia, patients’ 
organizations, regulatory bodies, health technology 
agencies (HTA) and health authorities, all having a 
shared desire to change and improve the current health-
care ecosystem. 
Specifically IMI 2 will:
- create cross disciplinary research to improve the ef-
ficiency of the entire medicines development process 
from discovery all the way through to patient access, 
thus improving access, quality and cost for more sus-
tainable health systems;
- conduct collaborative research focusing directly on 
generating innovative preventive and therapeutic treat-
ment options addressing priority healthcare challenges 
for Europe (i.e. where the burden of disease is the high-
est, not just of primary care but on the entire social se-
curity and labour system);
- provide a transparent platform facilitating engage-
ment of all key stakeholders in the provision of health-
care (i.e. healthcare practitioners, regulators, HTA 
agencies, patients and payers) to ensure that new sci-
entific advances are translated into effective healthcare 
solutions;
- provide training and infrastructure needs to support 
effective implementation of the research outcomes;
- drive widespread translation of the resulting and 
existing knowledge into innovative, effective products, 
strategies, interventions and services through long term 
and coordinated co-operation between all players in the 
healthcare ecosystem;
- create an integrated R&D framework that will at-
tract investment and in turn strengthen the competi-
tiveness of the European-based industries, creating new 
market opportunities increasing employment and eco-
nomic growth.
The new scenario of the establishement of three main 
RIs strategically important for biomedical research (EA-
TRIS, ECRIN and BBMRI) and the concomitant pro-
gress in the development of all other relevant RIs in the 
field of biomedical sciences – ERINHA for high safety 
level laboratory, Euro-bioimaging for biomedical imag-
ing infrastructure, Openscreen for screening platforms 
for chemical biology, and ELIXIR which underpins bio-
logical information and data storage for biomedical re-
search – will facilitate the cooperation between all these 
RI frameworks and the newly proposed public-private 
partnership (IMI 2), strengthening Europe’s impact in 
the area of biomedical research, further enhancing at-
tractiveness for global cooperation and collaboration, 
and ensuring efficient use of available research funding. 
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The new IMI 2 JTI is expected to start in January 
2014 and end in 2024. It will bring together the mem-
bers of the European Federation of Pharmaceutical 
Industries and Associations (EFPIA) and will also be 
open to other industries and sectors.
IMI 2 is based on equal sharing of cost between the 
EU budget and the private sector. The estimated budg-
et of IMI2 is € 3.45 billion. The EU will contribute up 
to € 1.725 billion from Horizon 2020, the next EU re-
search and innovation programme. This will match the 
in-kind EFPIA commitment of up to € 1.5 billion and 
an additional amount of up to € 225 million if other life 
science industries will decide to join and contribute to 
IMI 2 as members or associated partners in individual 
projects.
THE ECONOMIC AND SOCIETAL IMPACT
OF RIs
RIs are instrumental for the advancement of science 
and stimulate, through their excellence in research, in-
novation, learning and education processes, that are 
highly important for society and economy. In particu-
lar, the creation of the BMS RIs throughout Europe 
is expected to strengthen the scientific competitive-
ness of Europe as well as the attractiveness for indus-
try, by producing high quality tools and instruments 
and providing access to resources developed by all the 
European countries (healthcare databases, genetic 
databases, etc.) [11-14]. Furthermore, large RIs are 
strategic instruments to increase scientific integration 
within European countries and to reduce inequalities 
between them, fostering cooperation and providing the 
research community with the required access to inno-
vative methods and technologies. By favoring a climate 
of collaboration, sharing and exchange of knowledge, 
RIs can further strengthen the European position by 
encouraging mobility, improving training and educa-
tion, and attracting the best researchers from around 
the world. Thus, RIs can significantly contribute to hu-
man capital development, which is highly relevant for 
the local, national and European economy and for the 
society in general.
Concerning the benefits for researchers, the access to 
European facilities could trigger a positive mechanism 
on research. In fact, the use of a European infrastruc-
ture by international researchers is based on a peer-re-
viewed system, which impels the facility’s management 
to continuously evaluate and improve the standard of 
the equipment and the quality of the service. This also 
incentivizes the “local” user community to improve 
the quality of their access research proposals inducing 
a wider improvement in the quality of research and a 
greater effort to exploit and publish the outcomes of 
their use [17]. 
The participation in European RIs will also create the 
opportunity for access to European funding within Ho-
rizon 2020 framework, and will have an indirect impact 
at the national level by acting as an incentive to invest 
in national infrastructures and to promote translational 
and clinical research. The Italian participation in Euro-
pean RIs is expected to exert a positive impact on the 
Italian health system, in view of the RI importance in 
fostering translational medicine and of the future chal-
lenges for combining needs in public health and eco-
nomic availability.
CONCLUSIONS
Consistently with its mission of promoting transla-
tional research finalized to public health, the ISS has 
played a crucial role in ensuring and coordinating the 
Italian participation to three main BMS RIs (BBMRI, 
ECRIN and EATRIS), which have recently received the 
formal recognition of the ERIC status by the European 
Commission (EC).
This role has important implications both at a nation-
al level, where is mandatory to ensure a coordinated and 
qualified participation of many different institutions to 
these RIs, and at a European level. Notably, a national 
coordination for interconnected RIs is consistent with 
the EC policy, that oversees for the next future a strong 
interoperability among different RIs and continent-
wide initiatives to face public health challenges. 
From the national point of view, health services are 
decentralized in Italy from central to regional level of 
government and all stakeholders (national and regional) 
have their important relative weight. Thus, there is the 
urgency of finding well-established innovative solutions 
to rationalize integration of health knowledge into in-
novation, cost-saving and health improvement. 
In conclusion, interposed between regions and Eu-
rope, the ISS, as the major national research institute 
on public health in Italy, can play a unique role in al-
lowing a coordinated participation of excellence cent-
ers and reference institutes/facilities located in differ-
ent regions to these European RIs and is called to the 
urgent challenges of integrating and synergizing the 
investment in high-quality RIs, with the objective to al-
low major return through value generated by health in-
novation, healthcare optimization, and healthcare cost 
containment [11-14]. 
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